

CLAIMS

What is claimed is:

1. A method for treating or preventing SARS-CoV-2 virulence in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of any one of: SARS-CoV-2 E protein channel blocker and a SARS-CoV-2 3a protein inhibitor, thereby treating or preventing SARS-CoV-2 virulence in said subject.

2. The method of claim 1, wherein said preventing comprises preventing any one of: SARS-CoV-2 entry to a cell of said subject, uncoating of said SARS-CoV-2 in a cell of said subject, release of said SARS-CoV-2 from a cell of said subject, and any combination thereof.

3. The method of claim 1 or 2, wherein said subject is infected or suspected of being infected by SARS-CoV-2.

4. The method of any one of claims 1 to 3, wherein said SARS-CoV-2 E protein channel blocker is at least one molecule selected from the group consisting of: 5-Azacytidine, Memantine, Gliclazide, Mavorixafor, Saroglitazar Magnesium, Mebrofenin, Cyclen, Kasugamycin, Plerixafor, and any salt thereof.

5. The method of any one of claims 1 to 4, wherein said SARS-CoV-2 E protein channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.

6. The method of any one of claims 1 to 5, wherein said SARS-CoV-2 E protein channel blocker is Ginsenoside.

7. The method of any one of claims 1 to 5, wherein said SARS-CoV-2 E protein channel blocker is Memantine.

8. The method of any one of claims 1 to 7, wherein said SARS-CoV-2 3a protein inhibitor is at least one molecule selected from the group consisting of: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine, and Fludarabine.

9. The method of claim 8, wherein said SARS-CoV-2 3a protein inhibitor is Capreomycin.

10. A pharmaceutical composition comprising a SARS-CoV-2 E protein channel blocker and/or SARS-CoV-2 3a protein inhibitor for use in the treatment or prevention of SARS-CoV-2 virulence in a subject in need thereof.

11. The pharmaceutical composition of claim 10, wherein said prevention comprises prevention of any one of: SARS-CoV-2 entry to a cell of said subject, uncoating of said SARS-CoV-2, release of said SARS-CoV-2 from a cell of said subject, and any combination thereof.

12. The pharmaceutical composition of claim 10 or 11, wherein said SARS-CoV-2 E protein channel blocker is at least one molecule selected from the group consisting of: 5-Azacytidine, Memantine, Gliclazide, Mavorixafor, Saroglitasar, Magnesium, Mebrofenin, Cyclen, Kasugamycin, Plerixafor, and any salt thereof.

13. The pharmaceutical composition of claim 10 or 11, wherein said SARS-CoV-2 E protein channel blocker is Ginsenoside.

14. The pharmaceutical composition of any one of claims 10 to 13, wherein said SARS-CoV-2 3a protein inhibitor is at least one molecule selected from the group consisting of: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine, and Fludarabine.